A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 18 years of age
Locally advanced or metastatic (stage IIIB/IV) non-small cell lung cancer (NSCLC)
ECOG performance status 0-3
Treatment phase: histologically confirmed EGFR exon 19 deletion or exon 21 mutation in the diagnostic phase of the study
Adequate haematological, liver and renal function
Female patients must be postmenopausal, surgically sterile, or agree to use a barrier method of contraception
Male patients must be surgically sterile or agree to use a barrier method of contraception
You may not be if
Previous treatment for NSCLC with chemotherapy or therapy against EGFR, either with antibody or small molecule (tyrosine kinase inhibitor)
Symptomatic cerebral metastases
Pregnant or lactating women
Any other concomitant anti-cancer therapy (until disease progression and discontinuation of Tarceva therapy)
Clareo Health | A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
